Company Overview
RadNet, Inc. operates as a provider of outpatient diagnostic imaging services across the United States and internationally, functioning within the healthcare sector specifically under the diagnostics and research industry classification. This positioning places the company at the intersection of advanced medical technology and patient care delivery, focusing on high-demand modalities such as magnetic resonance imaging, computed tomography, and positron emission tomography. The enterprise maintains a substantial operational footprint employing 8,844 individuals, supported by a market capitalization of $4.86 billion and trailing twelve-month revenue of $2.04 billion. These valuation and revenue figures indicate that the company commands a significant position within its niche, reflecting strong market recognition despite current profitability challenges, as the market cap exceeds the annual revenue multiple.
Financial Health
The financial performance of RadNet, Inc. is characterized by revenue of $2.04 billion for the trailing twelve months, contrasted with a net income loss of -$18,652,000 and an EBITDA of $242.93 million. The substantial gap between the positive EBITDA and the negative net income reveals a cost structure heavily impacted by non-operating expenses, interest costs, or tax liabilities that erode bottom-line profitability despite strong operational cash generation. The company generated free cash flow of $180.29 million, which provides essential financial flexibility to fund operations, reduce debt obligations, or pursue strategic acquisitions without immediate reliance on external equity financing. Profitability metrics show a gross margin of 18.2%, an operating margin of 6.8%, and a profit margin of -0.9%, indicating that while the core service delivery model retains value, high overhead costs or interest expenses are currently preventing overall profitability. The balance sheet reflects a leveraged position with total debt of $1.86 billion against available cash of $767.21 million, resulting in a debt-to-equity ratio of 137.09%. This leverage suggests the company utilizes significant borrowed capital to finance its asset base, which increases financial risk but may enhance returns if earnings recover. Short-term liquidity is supported by a current ratio of 1.76, indicating that the company holds sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return on equity stands at 1.4% and return on assets at 1.6%, metrics that reveal management is currently generating minimal returns on the capital invested, reflecting the impact of the net loss on overall efficiency.
Valuation Assessment
Valuation multiples for RadNet, Inc. highlight a divergence between historical and future expectations, with a trailing P/E ratio listed as N/A due to the recent net loss and a forward P/E of 62.02. The absence of a trailing P/E combined with a high forward P/E implies that the market prices the stock based on anticipated future earnings recovery rather than current profitability. The price-to-book ratio is 4.45, suggesting the market assigns a significant premium to the company's assets, valuing the enterprise at more than four times its book value. Alternative valuation metrics include a price-to-sales ratio of 2.38 and an EV/EBITDA of 25.60, which provide context by valuing the company relative to its sales volume and operating cash generation before interest and taxes. Regarding price levels, the 52-week high is $85.84 and the 52-week low is $45.00, indicating a trading range of $40.84. Without the current share price explicitly provided in the facts, the precise percentage below the high cannot be calculated, but the range demonstrates significant volatility over the past year. The stock exhibits a beta of 1.46, meaning the share price is expected to be 46% more volatile than the broader market, reflecting the high sensitivity of the healthcare diagnostics sector to economic and regulatory shifts.
Growth & Income
Revenue growth for the company is recorded at 14.8% year-over-year, while earnings growth is N/A due to the current period's net loss. The disparity between robust revenue expansion and negative earnings growth implies that top-line gains have not yet translated to bottom-line profitability, likely due to the high fixed costs or interest expenses previously noted in the financial health section. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company retains all earnings and reinvests capital into growth initiatives rather than distributing cash to shareholders. The overall growth and income profile for RadNet, Inc. is defined by strong top-line expansion paired with a lack of dividend income, positioning the stock primarily as a vehicle for potential future equity appreciation rather than current income generation.